147 related articles for article (PubMed ID: 21629281)
1. Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy.
Nat Rev Drug Discov; 2011 Jun; 10(6):404. PubMed ID: 21629281
[No Abstract] [Full Text] [Related]
2. The New England Journal of Medicine publishes pivotal data demonstrating efficacy and safety of oral BG-12 (dimethyl fumarate) in multiple sclerosis.
Fox R
Can J Neurosci Nurs; 2012; 34(3):7-11. PubMed ID: 23362583
[No Abstract] [Full Text] [Related]
3. Oral therapy approved for multiple sclerosis.
Traynor K
Am J Health Syst Pharm; 2013 May; 70(9):744. PubMed ID: 23592350
[No Abstract] [Full Text] [Related]
4. The best clinical paper on multiple sclerosis in 2012.
Miller AE
Mult Scler; 2013 Apr; 19(5):520-1. PubMed ID: 23599182
[No Abstract] [Full Text] [Related]
5. Emerging multiple sclerosis oral therapies.
Rammohan KW; Shoemaker J
Neurology; 2010 Jan; 74 Suppl 1():S47-53. PubMed ID: 20038763
[TBL] [Abstract][Full Text] [Related]
6. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
7. Emerging disease-modifying oral therapies for multiple sclerosis.
Losy J; Kalinowska-Łyszczarz A
J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
[TBL] [Abstract][Full Text] [Related]
8. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
9. Oral fingolimod (gilenya) for multiple sclerosis.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
[No Abstract] [Full Text] [Related]
10. Management of psoriasis vulgaris and multiple sclerosis with fumaric acid.
Gkalpakiotis S; Arenberger P; Gkalpakioti P; Meluzinova E; Chandran D; Arenbergerova M
J Am Acad Dermatol; 2014 Mar; 70(3):e60-1. PubMed ID: 24528918
[No Abstract] [Full Text] [Related]
11. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
12. Principles of a new treatment algorithm in multiple sclerosis.
Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T
Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441
[TBL] [Abstract][Full Text] [Related]
13. Second oral MS drug wins FDA nod.
Sheridan C
Nat Biotechnol; 2013 May; 31(5):373. PubMed ID: 23657376
[No Abstract] [Full Text] [Related]
14. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
15. Dimethyl fumarate for multiple sclerosis.
Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
[TBL] [Abstract][Full Text] [Related]
16. [Comments on the contribution, "Immunomodulating staged therapy of multiple sclerosis by the Multiple Sclerosis Therapy Consensus Group"].
Störh M
Nervenarzt; 2002 Dec; 73(12):1207; author reply 1207. PubMed ID: 12599336
[No Abstract] [Full Text] [Related]
17. Marc Kirschner. Interview by Asher Mullard.
Kirschner M
Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
[No Abstract] [Full Text] [Related]
18. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate.
Wakkee M; Thio HB
Curr Opin Investig Drugs; 2007 Nov; 8(11):955-62. PubMed ID: 17979030
[TBL] [Abstract][Full Text] [Related]
19. Study critiques corporate control of trials.
Niiler E
Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
[No Abstract] [Full Text] [Related]
20. [Mitoxantrone for the treatment of patients with multiple sclerosis].
Komori M; Kondo T; Tanaka M
Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
